Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IK-930
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Ikena Oncology
Deal Size : $43.0 million
Deal Type : Financing
Details : The net proceeds will be used to expand and accelerate Ikena’s targeted oncology programs, including both IK-930, a TEAD1 selective Hippo pathway inhibitor, and IK-595, a MEK-RAF complexing inhibitor.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $43.0 million
July 08, 2023
Lead Product(s) : IK-930
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Ikena Oncology
Deal Size : $43.0 million
Deal Type : Financing
Lead Product(s) : PY314,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Ikena Oncology
Deal Size : Undisclosed
Deal Type : Acquisition
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
Details : Through the acquisition, Ikena gains all of Pionyr’s assets including, PY314 and PY159, targeting TREM2 and TREM1 respectively, which are designed to selectively deplete and in some cases reprogram certain tumor-associated macrophages responsible for i...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
July 08, 2023
Lead Product(s) : PY314,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Ikena Oncology
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : PY159,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Acquisition
Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement
Details : Gilead has waived its exclusive option to acquire Pionyr. Pionyr will be responsible for the development of its pipeline, including PY159, PY314 and PY265. PY159 targeting TREM1 and PY314 targeting TREM2 will continue to advance in Phase 1b studies in mu...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 23, 2023
Lead Product(s) : PY159,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : PY265
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PY265 is a monoclonal antibody targeting macrophage receptor with a collagenous structure (MARCO), a protein expressed on the surfaces of immuno-suppressive myeloid cells including tumor-associated macrophages (TAMs) and monocytic myeloid-derived suppres...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 11, 2022
Lead Product(s) : PY265
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PY159,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First in human clinical experience administering PY159 both alone and in combination with pembrolizumab including identification of target archival tumor specimens from participating patients.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 16, 2022
Lead Product(s) : PY159,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PY314,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PY314 was well tolerated over a range of doses both as a single agent and in combination with checkpoint inhibitor pembrolizumab at its label approved dose.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : PY314,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PY265
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Lonza Biologics Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development
Details : Lonza to provide cell line development, process development, drug substance and drug product manufacturing for Pionyr’s monoclonal antibody candidate intended for oncology indications.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 29, 2021
Lead Product(s) : PY265
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Lonza Biologics Inc
Deal Size : Undisclosed
Deal Type : Collaboration